Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US ...Middle East

STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand...

Read More Details
Finally We wish PressBee provided you with enough information of ( Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US )

Also on site :

• Palestinian activist Khalil denied release for son’s birth, wife says
• Education Ministry rehabilitates 70 schools since Assad regime’s fall
• Pope Francis’s will in full: Pontiff’s final wishes and place of burial